Ann: CEO presentation to Broker Meets Biotech - Perth, page-3

A nice presentation.  Good to see the company active.

The question was asked here recently by Fire bull about the commercial opportunity.  I've previously posted about Regranex as the most obvious comparison. This is the only FDA approved drug in the space and it was growing very quickly and reached $100m in sales before it was effectively pulled from the market because it was found to have a risk of cancer.

With Regranex effectively gone, all patients have left is bandages and this is why the commercial opportunity to me is very self evident and not something I lose any sleep over.

Also worth noting that Regranex was selling at a higher price ($2k) than FTT are proposing for VF001 ($1k) and so I'm not worried about our pricing being an issue commercially either.  In fact our ultimate pricing will be a function of the health economics package which is due in early 2019.

This study found that Regranex saved US$2400 per average patient so this likely represents the absolute ceiling for where pricing could go.  Ideally we would price around half this so the benefits are shared between FTT and the health care system.

http://www.japmaonline.org/doi/pdf/10.7547/15-004?code=pmas-site

See slide 13 of the presentation for more info on Regranex.